S

    SYBX (SYBX)

    Official site

    BIOTECHNOLOGY

    $1.22
    +0.01 (+0.62%)

    Last updated: Aug 28, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    76%(26/34)
    Avg Surprise
    +18.45%
    Streak
    3 Q
    PeriodReportedEst.SurpriseB/MYoY
    Sep 25
    		$-0.19N/AN/ABeat-1800.0%
    Jun 25
    		$-0.04$0.00N/ABeat-108.5%
    Mar 25
    		$-0.06$0.00N/ABeat+97.7%
    Dec 24
    		$0.85$-0.10+950.00%Beat+149.7%
    Sep 24
    		$-0.01N/A+94.44%Beat+99.6%
    Jun 24
    		$0.47$-0.51+192.16%Beat+323.8%
    Mar 24
    		$-2.60$-0.82-217.07%Miss-1030.4%
    Dec 23
    		$-1.71$-0.97-76.29%Miss-612.5%
    Sep 23
    		$-2.57$-2.67+3.75%Beat-928.0%
    Jun 23
    		$-0.21$-0.24+12.50%Beat+4.5%
    Mar 23
    		$-0.23$-0.23+0.00%Beat-4.5%
    Dec 22
    		$-0.24$-0.25+4.00%Beat-14.3%
    Sep 22
    		$-0.25$-0.23-8.70%Miss+13.8%
    Jun 22
    		$-0.22$-0.23+4.35%Beat+21.4%
    Mar 22
    		$-0.22$-0.23+4.35%Beat+38.9%
    Dec 21
    		$-0.21$-0.26+19.23%Beat+44.7%
    Sep 21
    		$-0.29$-0.29+0.00%Beat+19.4%
    Jun 21
    		$-0.28$-0.31+9.68%Beat+36.4%
    Mar 21
    		$-0.36$-0.39+7.69%Beat+21.7%
    Dec 20
    		$-0.38$-0.40+5.00%Beat-2.7%
    Sep 20
    		$-0.36$-0.47+23.40%Beat+7.7%
    Jun 20
    		$-0.44$-0.46+4.35%Beat+2.2%
    Mar 20
    		$-0.46$-0.43-6.98%Miss+9.8%
    Dec 19
    		$-0.37$-0.44+15.91%Beat+21.3%
    Sep 19
    		$-0.39$-0.48+18.75%Beat+9.3%
    Jun 19
    		$-0.45$-0.49+8.16%Beat+23.7%
    Mar 19
    		$-0.51$-0.54+5.56%Beat+7.3%
    Dec 18
    		$-0.47$-0.54+12.96%Beat+36.5%
    Sep 18
    		$-0.43$-0.63+31.75%Beat+74.1%
    Jun 18
    		$-0.59$-0.53-11.32%Miss+80.8%
    Mar 18
    		$-0.55$-0.73+24.66%Beat+34.5%
    Dec 17
    		$-0.74$-0.79+6.33%Beat+49.7%
    Sep 17
    		$-1.66$-0.50-232.00%Miss+8.8%
    Jun 17
    		$-3.08$-0.77-300.00%Miss-
    Mar 17
    		$-0.84$-0.70-20.00%Miss-
    Dec 16
    		$-1.47$-1.99+26.13%Beat-
    Sep 16
    		$-1.82$-2.13+14.55%Beat-

    Key Metrics

    Valuation
    P/E Ratio2.18EV/EBITDAN/A
    Price/FCF-3.94xFCF Yield-25.37%
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio9.19xQuick Ratio9.19x
    Trading Statistics
    BetaN/AAvg Volume59.67K
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.21
    SMA 20$1.20
    SMA 50$0.93
    SMA 200$0.86
    EMA 10$1.20
    EMA 20$1.15
    EMA 50$1.00
    EMA 200$0.93

    MACD

    Line: 0.08Signal: 0.10Hist: -0.02

    ADX

    ADX: 31.5+DI: 30.2-DI: 28.2

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down4.0
    PSAR$1.13

    Bollinger Bands

    Upper Band$1.25
    Lower Band$1.16
    %B Position745%(Upper)
    Band Width0.70

    RSI (14-Day)

    Neutral
    67.3

    Momentum Oscillators

    Stoch %K75.0
    Stoch %D68.5
    Williams %R-22.2
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)69.2
    MFI (14d)82.6

    Volatility Measures

    ATR (14d)$0.05(3.9%)
    StdDev (20d)0.02
    Hist Vol36.9%(Moderate)

    Volume Flow

    VWAP$1.21
    OBV630.6K
    AD Line-5.3M
    CMF (20d)0.484

    Volume Metrics

    Avg Vol (20d)26.3K
    Vol Ratio0.0x(Low)
    VWMA (20d)$1.21

    Pivot Points

    R3$1.21
    R2$1.21
    R1$1.21
    Pivot Point$1.21
    S1$1.21
    S2$1.21
    S3$1.21

    Advanced Oscillators

    TSI40.77
    Ultimate Osc65.5
    KST477.11

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$8,000$2.77M$393,000
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0$1.27M$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$8,000$2.77M$393,000
    Operating Expenses$1.00M$1.32M$1.34M$991,000$777,000$898,000$1.78M$748,000$-419,000$38.85M$13.41M$13.02M
    R&D$0$49,000$27,000$8,000$-14,000$22,000$-10,000$-713,000$2.20M$7.68M$10.14M$9.62M
    SG&A$828,000$1.06M$1.03M$818,000$800,000$836,000$1.40M$1.17M$1.18M$2.88M$3.27M$3.40M
    Operating Income$-1,012,000$-1,319,000$-1,342,000$-991,000$-777,000$-898,000$-1,776,000$-748,000$419,000$-38,845,000$-10,641,000$-12,623,000
    Interest Income$120,000$128,000$151,000$175,000$181,000$188,000$224,000$254,000$394,000$553,000$675,000$549,000
    Interest Expense$0$0$0$1.31M$0$0$24.54M$0$0$0$7.88M$0
    Income Before Tax$-543,000$681,000$1.82M$-2,301,000$-529,000$317,000$-26,320,000$-117,000$3.08M$0$-18,523,000$-12,075,000
    Income Tax Expense$0$0$0$0$0$0$0$0$5,000$0$0$3,000
    Net Income$-543,000$681,000$1.51M$-2,301,000$-529,000$317,000$-714,000$-117,000$3.08M$-25,606,000$-18,525,000$-12,078,000
    EBITDA$-663,000$553,000$1.36M$-2,476,000$-710,000$129,000$-938,000$-371,000$2.68M$-26,043,000$-19,101,000$-12,219,000
    EBIT$-663,000$553,000$1.36M$-2,476,000$-710,000$129,000$-938,000$-371,000$2.69M$-26,159,000$-19,198,000$-12,624,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SYBX

    News

    Synlogic and Caldera Therapeutics Announce Merger and $278 Million Private Placement

    Synlogic, Inc. and Caldera Therapeutics have announced a merger alongside a $278 million private placement. Mintz advised Synlogic, Fenwick & West advised Caldera Therapeutics, and Cooley advised the placement agents for Caldera Therapeutics. Access to the full details of this transaction requires a Standard 1 Year Membership to Global Legal Chronicle.

    Global Legal Chronicle•8/3/26•
    Bullish

    Mintz Advises Synlogic on Merger with Caldera Therapeutics and $278 Million Private Placement Financing

    Mintz advised Synlogic, Inc. on its definitive merger agreement with Caldera Therapeutics, Inc., forming a new company, Caldera Therapeutics, Inc., through an all-stock transaction. This merger is supported by an upsized $278 million concurrent private placement financing from a syndicate of new and existing investors. The transaction is expected to close concurrently with the merger.

    Mintz•7/30/26•
    Bullish

    Caldera, Synlogic Reverse Merge To Develop CLD-423 In Inflammatory Bowel Disease

    Caldera and Synlogic have announced a reverse merger to advance the development of CLD-423, a therapeutic candidate for Inflammatory Bowel Disease. The merger aims to combine the resources and expertise of both companies to further the clinical progress of this drug. This move signifies a strategic alliance within the pharmaceutical sector, focusing on specific disease areas.

    insights.citeline.com•7/30/26•
    Bullish

    Synlogic and Caldera sign merger agreement

    Synlogic and Caldera Therapeutics have announced a definitive merger agreement, forming a combined company that will be a 100%-owned subsidiary of Caldera Therapeutics, a newly formed holding company. This merger is supported by a concurrent private placement aiming to raise approximately $278 million, which will fund the Phase II clinical development of Caldera’s CLD-423 for ulcerative colitis and Crohn’s disease. The new entity, expected to trade on Nasdaq under "CALD", anticipates its cash reserves and private placement proceeds will support operations until 2029.

    Pharmaceutical Technology•7/30/26•
    Bullish

    Synlogic (SYBX) holder NEA reports 25% stake and backs Caldera merger

    New Enterprise Associates 14, a major shareholder in Synlogic, has updated its beneficial ownership report, confirming a 25.0% stake in the company. NEA 14 supports Synlogic's planned merger with Caldera Therapeutics and Sonic Holdco, and has entered into support agreements to vote in favor of the merger. Additionally, the warrant exercise price for NEA 14's purchase warrants has been reduced to $0.70 per share, and their cash redemption right has been removed.

    Stock Titan•7/30/26•
    Somewhat-Bullish

    Frequently Asked Questions About SYBX

    Does SYBX pay dividends?
    SYBX (SYBX) does not currently pay a regular dividend.
    What is SYBX's P/E ratio?
    SYBX has a price-to-earnings (P/E) ratio of 2.18.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In